Sc5b-9 plasma levels in human healthy volunteers of the Phase I trial. Seventy-two healthy volunteers were administered increasing i.v. doses of either TRO40303 or placebo as described in the materiel and method section. Plasma level of SC5b-9 was dosed in all subjects before administration, and then 5, 15 and 60 min after end of infusion. Percent evolution from baseline is presented for each subject. Dose and flow rate groups are indicated by colour code. Plain circles represent subjects having received TRO40303 and open circles, subjects having received the placebo.